V-Square Quantitative Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

V-Square Quantitative Management’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$552K	Buy	2,238 +27	+1%	+$6.87K	0.05%	320
2026 Q2	$666K	Buy	2,211 +242	+12%	+$73K	0.06%	266
2026 Q1	$651K	Buy	1,969 +11	+0.6%	+$3.74K	0.07%	253
2025 Q4	$779K	Buy	+1,958	New	+$867K	0.08%	208
2025 Q3	–	Sell	-1,692	Closed	-$552K	–	184
2025 Q2	$552K	Buy	1,692 +1,321	+356%	+$366K	0.07%	275
2025 Q1	$100K	Buy	371 +1	+0.3%	+$257	0.01%	540
2024 Q4	$87.1K	Buy	370 +14	+4%	+$3.68K	0.01%	544
2024 Q3	$97.9K	Buy	356 +22	+7%	+$5.73K	0.01%	537
2024 Q2	$81.2K	Buy	334 +60	+22%	+$9.47K	0.01%	543
2024 Q1	$40.9K	Hold	274	–	–	0.01%	554
2023 Q4	$52.4K	Buy	+274	New	+$46.7K	0.01%	549
2023 Q3	–	Sell	-279	Closed	-$53K	–	507
2023 Q2	$53K	Buy	+279	New	+$55.3K	0.04%	293

Other funds holding ALNY

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

IFM Investors Melbourne, Australia $16B AUM 33.69% 1-Year Est. Return

Portman Square Capital London, United Kingdom $1.77B AUM 15.29% 1-Year Est. Return

PensionDanmark Copenhagen O, Denmark $12.3B AUM 33.99% 1-Year Est. Return

Sumitomo Mitsui DS Asset Management Tokyo, Japan $14.8B AUM 30.39% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

V-Square Quantitative Management's ALNY Position: Q3 2026 in Review

V-Square Quantitative Management increased its Alnylam Pharmaceuticals (ALNY) stake by 1.2% in Q3 2026, buying an estimated $6.87K and bringing the position to 2,238 shares worth $552K. The position accounts for 0.05% of the portfolio, ranked #320.

V-Square Quantitative Management first reported a position in ALNY in Q2 2023 and has held it in 12 quarters since. The position peaked at $779K in Q4 2025. 92 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

V-Square Quantitative Management held 2,238 shares of Alnylam Pharmaceuticals worth $552K as of Q3 2026.
V-Square Quantitative Management bought 27 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $6.87K.
Alnylam Pharmaceuticals made up 0.05% of V-Square Quantitative Management's portfolio in Q3 2026, its #320 holding.
V-Square Quantitative Management first reported a position in Alnylam Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
V-Square Quantitative Management's Alnylam Pharmaceuticals position peaked at $779K in Q4 2025.
92 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on V-Square Quantitative Management's 13F filing for Q3 2026, filed 15 Oct 2026.